Outcomes of NSCLC patients with positive EGFR mutation

被引：0
|
作者：
Diver, Sarah
Haris, Mohammed
Khan, Shahul Leyakathali
Kerr, Jane
Edwards, Jane
Munavvar, Mohammed
机构：
[1] Royal Preston Hosp, Med, Preston PR2 9HT, Lancs, England
[2] Royal Preston Hosp, Resp Med, Preston PR2 9HT, Lancs, England
[3] Royal Preston Hosp, Pathol, Preston PR2 9HT, Lancs, England
来源：
EUROPEAN RESPIRATORY JOURNAL | 2012年 / 40卷
关键词：
Lung cancer / Oncology;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
3269
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EGFR MUTATION IN AUSTRIAN PATIENTS WITH NSCLC: A RETROSPECTIVE STUDY
    Hochmair, M. J.
    Miler, M.
    Setinek, U.
    Kirchbacher, K.
    Mohn-Staudner, A.
    Kaufmann, M.
    Kapfhammer, I.
    Arns, M. B.
    Patocka, K.
    Burghuber, O. C.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S66 - S66
  • [32] Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC
    Hamaguchi, Reo
    Okamoto, Toshihiro
    Sato, Masaaki
    Hasegawa, Michiko
    Wada, Hiromi
    ANTICANCER RESEARCH, 2017, 37 (09) : 5141 - 5145
  • [33] Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs
    Matsuoka, Hiromichi
    Kaneda, Hiroyasu
    Sakai, Kazuko
    Koyama, Atsuko
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    CLINICAL LUNG CANCER, 2017, 18 (01) : E85 - E87
  • [34] EGFR mutation in NSCLC in Pakistan
    Ahmed, Z. A.
    Moatter, T.
    Pervez, S.
    Khan, W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia
    Webb, Suzanne
    Thomas, Marc
    Metcalf, Cecily
    Segal, Amanda
    Nowak, Anna K.
    Bentel, Jacqueline
    Millward, Michael
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (01) : 66 - 71
  • [36] Increased Progression Free Survival of Patients with EGFR positive mutation NSCLC Treated with Afatinib in Regard to Toxicity
    Pratiwi, S. D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S672 - S672
  • [37] PANORAMA - Real world molecular testing, treatment patterns, and clinical outcomes in patients with EGFR mutation-positive locally advanced or advanced NSCLC
    Griesinger, F.
    Buettner, R.
    Deppermann, K. -M.
    Reinmuth, N.
    Schuette, W.
    Thomas, M.
    Bergner, S.
    Schumann, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 248 - +
  • [38] TREATMENTS FOR EGFR MUTATION-POSITIVE (M plus ) NSCLC PATIENTS - A NETWORK META-ANALYSIS (NMA) BY MUTATION TYPE
    Popat, S.
    Yang, J. C. H.
    Lungershausen, J.
    Griebsch, I
    Marten, A.
    Wu, Y. L.
    VALUE IN HEALTH, 2014, 17 (07) : A615 - A615
  • [39] CLINICAL OUTCOMES AFTER FIRST-LINE EGFR-TKI FOR PATIENTS WITH NSCLC, EGFR MUTATION, AND POOR PERFORMANCE STATUS
    Nagamata, Makoto
    Okuma, Yusuke
    Sunami, Kuniko
    Hosomi, Yukio
    Okamura, Tatsuru
    ANNALS OF ONCOLOGY, 2014, 25
  • [40] Clinical Outcomes After First-line EGFR Inhibitor Treatment for Patients with NSCLC, EGFR Mutation, and Poor Performance Status
    Okuma, Yusuke
    Hosomi, Yukio
    Nagamata, Makoto
    Yamada, Yuko
    Sekihara, Kuniko
    Kato, Kan
    Hishima, Tsunekazu
    Okamura, Tatsuru
    ANTICANCER RESEARCH, 2013, 33 (11) : 5057 - 5064
12345